Profile for Cyprus Patent: 2018
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Cyprus Patent: 2018
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 8,337,824 | May 29, 2030 | Vifor Pharma | VELTASSA | patiromer sorbitex calcium |
| 8,071,623 | Mar 27, 2031 | Glaxosmithkline | ZEJULA | niraparib tosylate |
| 8,071,623 | Mar 27, 2031 | Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate |
| 11,090,294 | Nov 29, 2030 | Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate |
| 11,090,294 | Nov 29, 2030 | Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate |
| 12,396,986 | Nov 29, 2030 | Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate |
| 12,396,986 | Nov 29, 2030 | Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
